cas_call({"xm":"李媛媛","xb":"女","zc":"研究员","xl":"博士","dh":"0760-85281627 转8388","cz":"0766-85283266","dzyj":"liyuanyuan@simm.ac.cn","grzy":"","zjlb":"研究员","zw":"课题组长","txdz":"广东省中山市火炬开发区(翠亨新区)中瑞欧工业园健康医药示范区A栋302","grjj":"

李媛媛，研究员，课题组长。主要从事代谢性疾病，例如非酒精性脂肪肝病(NAFLD\/NASH)，糖尿病以及其并发症动脉粥样硬化等的致病机理研究以及创新药物开发。实验室主要致力于发现新颖的致病信号通路并阐明其致病机理，同时在此过程中寻找有潜力的代谢性疾病治疗靶点进行创新药物研发。基础研究方面，目前已发表学术论文23篇，分别发表于代谢领域权威杂志Cell Metabolism, Hepatology, Nature Communications, Diabetes等。发表文章得到Nature Reviews Endocrinology，Hepatology, Diabetes 等杂志的高度评价，且得到Faculty of 1000 肝病领域权威专家的推荐。文章总引用953次，H-index 17。药物研发方面，作为主要参与人之一开发了10多个新颖的有潜力的二型糖尿病小分子化合物，申请中国专利一项，其中有些候选药物已经拿到临床批件，实现成果转化。参与承担多项美国国立卫生研究院NIH代谢性疾病R01研究基金，主持NIH T32肝肠方向培训基金。<\/font><\/p>\n

教育经历：<\/span><\/p>\n

\n<\/span><\/p>\n

2004.9–2010.1 中国科学院上海药物研究所，博士<\/span><\/p>\n

\n<\/span><\/p>\n

<\/p>\n

2000.9–2004.6 华中科技大学同济医学院药学院，学士<\/span><\/p>","yjfx":"

非酒精性脂肪肝病，糖尿病及其并发症动脉粥样硬化的致病机理研究及创新药物开发<\/p>","dblz":"

1. Yuanyuan Li#,<\/strong> Yanyong Xu#, Kavita Jadhav, Liya Yin and Yanqiao Zhang. Hepatic forkhead box protein A3 regulates ApoA I expression, cholesterol efflux and atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology<\/em>, 2019, 39(8):1574-1587<\/font><\/p>\n

2. Yuanyuan Li<\/strong>, Munaf Zalzala, Kavita Jadhav, Yang Xu, Takhar Kasumov, Liya Yin and Yanqiao Zhang. Carboxylesterase 2 Prevents Liver Steatosis by Modulating Lipolysis, ER stress and Lipogenesis and is regulated by Hepatocyte Nuclear Factor 4 Alpha in Mice. Hepatology<\/em>, 2016, 63:1860-1874<\/font><\/p>\n

3. Jiesi Xu #, Yuanyuan Li<\/strong> #, Wei Dong Chen #, Yang Xu #, Liya Yin, Xuemei Ge, Kavita Jadhav, Luciano Adorini, and Yanqiao Zhang. Hepatic Carboxylesterase 1 Is Essential for Both Normal and Farnesoid X Receptor Controlled Lipid Homeostasis. Hepatology<\/em>, 2014, 59:1761-1771 (# Co-first author) Received Editorial Comment in Hepatology, 2014 59:1665-7 and Highlighted by Faculty of 1000<\/font><\/p>\n

4. Yuanyuan Li<\/strong>, Kavita Jadhav, and Yanqiao Zhang. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol<\/em>, 2013, 86(11):1517-24<\/font><\/p>\n

5. Yuan-Yuan Li#,<\/strong> Li-Fang Yu#, Li-Na Zhang, Bei-Ying Qiu, Ming-Bo Su, Fang Wu, Tao Pang, Min Gu, Wei Zhang, Da-Kai Chen,Wei-Ping Ma, Jing-Ya Li*, Fa-Jun Nan*, Jia Li*. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db\/db mice. Toxicol Appl Pharm<\/em>, 2013, 273(2):325-34<\/font><\/p>\n

6. Li-Fang Yu#, Yuan-Yuan Li#,<\/strong> Ming-Bo Su, Mei Zhang , Wei Zhang , Li-Na Zhang , Tao Pang , Run-Tao Zhang , Bing Liu , Jing-Ya Li*, Jia Li*, and Fa-Jun Nan*. Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators. ACS Med. Chem. Lett., 2013, 4 (5): 475–480 (# Co-first author)<\/font><\/p>\n

7. Linrong Zhu#, Yuanyuan Li#,<\/strong> Qiu Ling, Mingbo Su, Xin Wang, Chunmei Xia, Yi Qu, Jingya Li, Jia Li*, Bin Xiong*, Jingkang Shen*. Design and Synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as Dipeptidyl Peptidase IV Inhibitors. ChemMedChem, 2013, 8(7):1104-16 (# Co-first author)<\/font><\/p>\n

8. Zhang Liu#, Qian Chai #, Yuanyuan Li<\/strong> #, Qiang Shen, Lanping Ma*, Lina Zhang, Xin Wang, Li Sheng, Jingya Li, Jia Li*, Jingkang Shen. Discovery of novel PTP1B inhibitors with antihyperglycemic activity. Acta Pharmacologica Sinica, 2010, 31:1005–1012 (# Co-first author)<\/font><\/p>\n

9. Yanyong Xu, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li<\/strong>, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, Yanqiao Zhang. Lipocalin‐2 Protects Against Diet‐Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes. Hepatology Communications, 2019, 3:763-775<\/font><\/p>\n

10. Kavita Jadhav#, Yang Xu#, Yanyong Xu#, Yuanyuan Li<\/strong>, Jiesi Xu, Yingdong Zhu, Luciano Adorini, Yoon Kwang Lee, Takhar Kasumov, Liya Yin, Yanqiao Zhang. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Molecular Metabolism, 2018, 9:131-140<\/font><\/p>\n

11. Jiesi Xu, Yang Xu, Yuanyuan Li<\/strong>, Kavita Jadhav, Min You, Liya Yin & Yanqiao Zhang (2016). Carboxylesterase 1 Is Regulated by Hepatocyte Nuclear Factor 4α and Protects Against Alcohol- and MCD diet-induced Liver Injury. Scientific Reports, 2016, 6:24277<\/font><\/p>\n

12. Michael L. Multhaup, Marcus M. Seldin, Andrew E. Jaffe, Xia Lei, Henriette Kirchner, Prosenjit Mondal, Yuanyuan Li<\/strong>, Varenka Rodriguez, Alexander Drong, Mehboob Hussain, Cecilia Lindgren, Mark McCarthy, Erik Naslund, Juleen R. Zierath, G. William Wong, Andrew P. Feinberg. Mouse-Human Experimental Epigenetic Analysis Unmasks Dietary Targets and Genetic Liability for Diabetic Phenotypes. Cell Metabolism, 2015, 21(1):138-49 Received Editorial Comment in Nature Reviews Endocrinology<\/em>, 2015:11(5):261-2<\/font><\/p>\n

13. Yang Xu#, Munaf Zalzala#, Jiesi Xu, Yuanyuan Li<\/strong>, Liya Yin, Yanqiao Zhang. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nature communications, 2015, 6:7466<\/font><\/p>\n

14. Prosenjit Mondal#, Woo-Jin Song#, Yuanyuan Li<\/strong>, Kil S. Yang, and Mehboob A. Hussain. Increasing β-Cell Mass Requires Additional Stimulation for Adaptation to Secretory Demand. Mol Endocrinol., 2015, 29(1):108-20<\/font><\/p>\n

15. Ryan C. Riddle, Julie M. Leslie, Mathieu Ferron, Yuanyuan Li,<\/strong> Douglas J.Digirolamo, Marie-Claude Faugere, Mehboob A. Hussain, Gerard Karsenty and Thomas L. Clemens. Tsc2 Is a Molecular Checkpoint Controlling Osteoblast Development and Glucose Homeostasis. Mol Cell Biol., 2014:34(10):1850-62<\/font><\/p>\n

16. Jiesi Xu, Liya Yin, Yang Xu, Yuanyuan Li, Munaf Zalzala, Gang Cheng, Yanqiao Zhang. Hepatic Carboxylesterase 1 Is Induced by Glucose and Regulates Postprandial Glucose Levels. PLoS ONE, 2014, 9(10):e109663<\/font><\/p>\n

17. Woo-Jin Song#, Prosenjit Mondal#, Yuanyuan Li<\/strong>, Suh Eun Lee and Mehboob A. Hussain. Pancreatic β-cell Response to Increased Metabolic Demand and to Pharmacologic Secretagogues Requires EPAC2A. Diabetes, 2013, 62(8):2796-807 Received Editorial Comment in Diabetes, 2013,62(8):2665-6<\/font><\/p>\n

18. Li-Na Zhang, Hua-Yong Zhou, Yan-Yun Fu, Yuan-Yuan Li<\/strong>, Fang Wu, Min Gu, Ling-Yan Wu, Chun-Mei Xia, Tian-Cheng Dong, Jing-Ya Li*, Jing-Kang Shen*, and Jia Li*. Novel Small-Molecule PGC-1α Transcriptional Regulator With Beneficial Effects on Diabetic db\/db Mice. Diabetes, 2013, 62(4):1297-307<\/font><\/p>\n

19. Li-Na Zhang, Lei Xu, Hua-Yong Zhou, Ling-Yan Wu, Yuan-Yuan Li,<\/strong> Tao Pang, Chun-Mei Xia, Bei-Ying Qiu, Min Gu, Tian-Cheng Dong, Jing-Ya Li*, Jing-Kang Shen*, Jia Li*. Novel Small-Molecule AMP-Activated Protein Kinase Allosteric Activator with Beneficial Effects in db\/db Mice. PLoS ONE, 2013, 8(8):e72092<\/font><\/p>\n

20. Beiying Qiu, Turner N, Yuanyuan Li,<\/strong> Ming Gu, Mingwei Huang, Fang Wu, Tao Pang, Fajun Nan, Jiming Ye, Jingya Li*, Jia Li*. High-Throughput Assay for Modulators of Mitochondrial Membrane Potential Identifies a Novel Compound With Beneficial Effects on db\/db Mice. Diabetes, 2010, 59:256–265<\/font><\/p>\n

21. Zhe Cheng#, Anfeng Chen#, Fang Wu, Li Sheng, Hankun Zhang, Min Gu, Yuanyuan Li<\/strong>, Lina Zhang, Lihong Hu*, Jingya Li*, Jia Li*. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorganic & Medicinal Chemistry, 2010, 18:5915–5924<\/font><\/p>\n

22. Guanghui Deng, Deju Ye, Yuanyuan Li<\/strong>, Lingyan He, Yu Zhou, Jiang Wang, Jia Li, Hualiang Jiang, Hong Liu. Synthesis of (S)-, (R)-, and (rac)-2-amino-3,3-bis(4-fluorophenyl) propanoic acids and an evaluation of the DPP IV inhibitory activity of Denagliptin diastereomers. Tetrahedron, 2008, 64(46):10512-10516<\/font><\/p>\n

23. Xiang Guang-ya, Liang Rong-bei, Li Yan-ping, Li Yuanyuan<\/strong>. Synthesis of NO-releasing oxaprozin and determination of NO-releasing activities in vitro. Central South Pharmacy, 2005, 3(4):206<\/font><\/p>\n <\/font>\n

<\/p>\n

<\/p>","jyjl":"","gzjl":"

\n
2020.8至今<\/label>\n
中国科学院上海药物研究所，研究员，课题组长<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2019.10–2020.6<\/label>\n
美国贝勒医学院，博士后<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2012.9–2018.4<\/label>\n
美国东北俄亥俄医科大学，博士后<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2010.9–2012.8<\/label>\n
美国约翰霍普金斯大学医学院，博士后<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>","ktxm":"
","ryhj":"

\n
2020年<\/label>\n
美国国立卫生研究院(NIH)T32 培训基金(肝肠方向)<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2016年<\/label>\n
美国肝病会议优秀年轻研究学者旅行奖<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2016年<\/label>\n
美国肝病会议杰出学术海报奖<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2014年<\/label>\n
美国心血管会议优秀口头报告奖<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n

\n
2010年<\/label>\n
上海市优秀博士毕业生<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>","xpwj":"http://sourcedb.simm.cas.cn/zw/gb2020/yjzz/202101/P020210105346305815967.jpg","kycg":"
1.首次发现肝脏羧酸酯酶CES1,CES2参与非酒精性脂肪肝致病机理，是新颖的肝脏甘油三酯水解酶，可以作为非酒精性脂肪肝病的治疗靶点；同时与美国Intercept公司合作，阐明了其公司研发的目前唯一一个通过非酒精性脂肪肝炎三期临床的候选药物奥贝胆酸的降脂机制。研究成果发表于肝病领域专业杂志Hepatology,2014:59:1761-1771与Hepatology, 2016:63:1860-1874; 发表文章被当期Hepatology杂志高度评价，得到Faculty of 1000 推荐。<\/div>\n
<\/div>\n
2.首次发现了动脉粥样硬化的新的致病通路: FOXA3-ApoAI 通路，miRNA34a-HNF4α等通路。并且使用目前FDA已经批准的基因治疗手段AAV病毒载体，证明AAV8-FOXA3是一种潜在的非酒精性脂肪肝并发的动脉粥样硬化的治疗手段。相关成果发表在动脉粥样硬化领域专业杂志Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39(8):1574-1587, Nature communications, 2015:6:7466以及Nature Metabolism(under revision)<\/div>\n
<\/div>\n
3.参与开发了10多个新颖的治疗二型糖尿病小分子化合物，如AMPK 激活剂，选择性DPPIV抑制剂，PTP1B抑制剂等。其中，AMPK 激活剂与Roche罗氏中国研发中心合作；DPPIV抑制剂已经拿到临床批件，实现成果转化；相关成果发表在Toxicol Appl Pharm, 2013:273(2):325-34， ACS Med. Chem. Lett., 2013:4 (5): 475–480，ChemMedChem, 2013:8(7):1104-16，Acta Pharmacologica Sinica, 2010:31:1005–1012以及申请专利PCT\/CN2006\/001596<\/div>","shrz":" ","puburl":"http://sourcedb.simm.cas.cn/zw/gb2020/yjzz/202101/t20210105_5850402.json"});